Focused On-demand Library for C-X-C chemokine receptor type 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

CDw128b; GRO/MGSA receptor; High affinity interleukin-8 receptor B; IL-8 receptor type 2

Alternative UPACC:

P25025; Q8IUZ1; Q9P2T6; Q9P2T7


C-X-C chemokine receptor type 2 (CXCR2), also known as high affinity interleukin-8 receptor B, plays a pivotal role in immune responses. It functions as a receptor for interleukin-8, a potent neutrophil chemotactic factor, facilitating the activation of neutrophils through a G-protein mediated phosphatidylinositol-calcium second messenger system. CXCR2 binds to IL-8 with high affinity, alongside other ligands such as CXCL3, GRO/MGSA, and NAP-2.

Therapeutic significance:

CXCR2's involvement in WHIM syndrome 2, characterized by warts, hypogammaglobulinemia, infections, and myelokathexis, underscores its therapeutic potential. Targeting CXCR2 could lead to innovative treatments for this immunodeficiency disorder, offering hope for patients with this and potentially other neutrophil-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.